nVerses Capital’s Travere Therapeutics TVTX Stock Holding History

nVerses Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,200	Closed	-$32.4K	–	1214
2024 Q1	$32.4K	Buy	+4,200	New	+$35.4K	0.08%	335

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

nVerses Capital's TVTX Position: Q2 2024 in Review

nVerses Capital sold out of Travere Therapeutics (TVTX) in Q2 2024, closing a stake of 4,200 shares — an estimated $32.4K sold.

nVerses Capital first reported a position in TVTX in Q1 2024 and held it in 1 quarter. The position peaked at $32.4K in Q1 2024. 173 funds tracked by Wall St. Rank hold TVTX as of Q2 2024.

nVerses Capital reported no remaining Travere Therapeutics position as of Q2 2024 after selling out during the quarter.
nVerses Capital sold 4,200 Travere Therapeutics shares in Q2 2024, an estimated $32.4K.
nVerses Capital first reported a position in Travere Therapeutics in Q1 2024 and held it in 1 quarter.
nVerses Capital's Travere Therapeutics position peaked at $32.4K in Q1 2024.
173 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2024.

Based on nVerses Capital's 13F filing for Q2 2024, filed 31 Jul 2024.